🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07368829
Recruiting Not applicable

AI-Driven Autonomous Registration in Robotic Bronchoscopy

NCT07368829 · tracked via the Priya Life Science China tracker
Sponsor
Ruijin Hospital
Phase
Not applicable
Started
2026-03-01
Last updated
2026-04-13

Condition(s) studied

Lung NodulesBronchoscopyLocalization Efficiency

Investigational drug(s) / intervention(s)

AI-driven autonomous registration

AI-driven autonomous registration: All participants in this arm will undergo robotic navigational bronchoscopy and pulmonary nodule localization performed using the Langhe Bronchoscopy Robot System. The key intervention is the use of artificial intelligence (AI)-driven autonomous registration technology to automatically align the pre-operative chest CT images with the real-time bronchoscopic anatomy prior to the procedure. This process aims to reduce reliance on the conventional, operator-dependent manual registration. Physicians will supervise the entire process and perform necessary manual intervention if the AI registration is unsatisfactory or for safety reasons.

Study summary

This study aims to evaluate the feasibility and safety of an artificial intelligence (AI)-driven autonomous registration technology in robotic navigational bronchoscopy. A total of 20 patients with pulmonary nodules requiring localization will be enrolled. The Langhe Bronchoscopy Robot System equipped with AI-based autonomous registration software will be used. Primary outcomes include the success rate of autonomous registration and the rate of manual intervention during the process. Secondary outcomes encompass registration time, complication rates, and nodule localization success.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years. * Radiologically confirmed pulmonary nodules requiring preoperative localization. * Scheduled for robotic navigational bronchoscopy using the Bronchoscopy Robot System. * Willing to provide written informed consent. Exclusion Criteria: * Severe cardiopulmonary dysfunction (e.g., FEV1 \< 30% predicted). * Coagulopathy or anticoagulation therapy that cannot be safely interrupted. * Pregnancy or lactation. * Inability to tolerate bronchoscopy under general anesthesia.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai Shanghai Municipality Recruiting

More Ruijin Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07368829 on ClinicalTrials.gov ↗ ← All trials in China